Phase I Study of PN401, Fluorouracil, Leucovorin and CPT-11 in Patients With Solid Tumors
Status:
Terminated
Trial end date:
2004-03-01
Target enrollment:
Participant gender:
Summary
CPT-11 and 5Fluorouracil (5FU) combined with leucovorin has become the standard of care for
colorectal cancer. PN401 permits treatment with higher than normal doses of 5FU, which could
increase its therapeutic potential. It is hypothesized that adding PN401 to the CPT-11, 5FU,
leucovorin regimen will reduce toxicity and will allow higher doses of 5FU to be well
tolerated and therefore potentially increase effectiveness.